Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

January 25, 2023

Study Completion Date

March 20, 2023

Conditions

Sturge-Weber SyndromeGlaucomaOcular Hypertension

Interventions

DRUG

QLS-101 ophthalmic solution, 2.0 %

ophthalmic solution in a single use dropper vial

Trial Locations (1)

Duke Eye Center, Durham

All Listed Sponsors

lead

Qlaris Bio, Inc.

INDUSTRY